Ageing and metabolism: Drug discovery opportunities

Nature Reviews Drug Discovery

Volumn 4, Issue 7, 2005, Pages 569-580

  Curtis, Rory ^a   Geesaman, Bard J ^a   DiStefano, Peter S ^a  

^a Elixir Pharmaceuticals Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACARBOSE; ACETYL COENZYME A CARBOXYLASE; ACETYLSALICYLIC ACID; ADALIMUMAB; ADENYLATE KINASE; ANOREXIGENIC AGENT; ANTIDIABETIC AGENT; ANTINEOPLASTIC AGENT; ANTIOBESITY AGENT; CARRIER PROTEIN; ETANERCEPT; GHRELIN RECEPTOR ANTAGONIST; GROWTH HORMONE; GW 501506; HYDROLASE INHIBITOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INFLIXIMAB; INSULIN; LIGASE INHIBITOR; LITHIUM; MELANIN CONCENTRATING HORMONE RECEPTOR ANTAGONIST; MELANOCORTIN 4 RECEPTOR AGONIST; METFORMIN; MIGLITOL; MONOCLONAL ANTIBODY; NETOGLITAZONE; OCTREOTIDE; PEGVISOMANT; PENTOXIFYLLINE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR AGONIST; PHOSPHOTRANSFERASE INHIBITOR; PROTEIN INHIBITOR; RAPAMYCIN; RAPAMYCIN DERIVATIVE; RECEPTOR BLOCKING AGENT; RIMONABANT; SIBUTRAMINE; SILENT INFORMATION REGULATOR PROTEIN 2; SOMATOMEDIN C RECEPTOR ANTAGONIST; SULFONYLUREA; TETRAHYDROLIPSTATIN; UNCLASSIFIED DRUG;

ADIPOCYTE; AGING; BODY WEIGHT DISORDER; CALORIC RESTRICTION; CELL FUNCTION; CLINICAL TRIAL; DISEASE RESISTANCE; DRUG RESEARCH; DRUG TARGETING; DYSLIPIDEMIA; ENERGY BALANCE; ENERGY METABOLISM; FOOD INTAKE; GENETIC CONSERVATION; GROWTH HORMONE DEFICIENCY; HUMAN; HYPERCHOLESTEROLEMIA; LIFESPAN; MALIGNANT NEOPLASTIC DISEASE; METABOLIC DISORDER; METABOLIC REGULATION; MOLECULAR DYNAMICS; MOLECULAR EVOLUTION; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; PHENOTYPIC VARIATION; PRIORITY JOURNAL; REGULATORY MECHANISM; REVIEW; WEIGHT GAIN;

ADIPOCYTES; AGING; ANIMALS; DRUG DESIGN; EATING; HUMANS; INSULIN; LIFE EXPECTANCY; METABOLISM; MULTIENZYME COMPLEXES; PROTEIN-SERINE-THREONINE KINASES;

EID: 22144499162     PISSN: 14741776     EISSN: None     Source Type: Journal    
DOI: 10.1038/nrd1777     Document Type: Review

References (225)

1. Weindruch, R. & Walford, R. L. The retardation of aging and disease by dietary restriction (C. C. Thomas, Springfield, III., 1988).
2. Masoro, E. J. Subfield history: caloric restriction, slowing aging, and extending life. Sci. Aging Knowledge Environ. 2003, RE2 (2003).
3. Kenyon, C. The plasticity of aging: insights from long-lived mutants. Cell 120, 449-60 (2005).
4. National Cholesterol Education Program (US). Expert Panel on Detection Evaluation and Treatment of High Blood Cholesterol in Adults. Third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (adult treatment panel III): final report (The Program, Washington, DC, 2002).
5. Chumlea, W. C., Rhyne, R. L., Garry, P. G. & Hunt, W. C. Changes in anthropometric indices of body composition with age in a healthy elderly population. Am. J. Human. Biol. 1, 457-462 (1989).
6. Bouchard, C., Despres, J. P. & Mauriege, P. Genetic and nongenetic determinants of regional fat distribution. Endocr. Rev. 14, 72-93 (1993).
7. Ohlson, L. O. et al. The influence of body fat distribution on the incidence of diabetes mellitus. 13. 5 years of follow-up of the participants in the study of men born in 1913. Diabetes 34, 1055-1058 (1985).
8. Manson, J. E. et al. Body weight and mortality among women. N. Engl. J. Med. 333, 677-685 (1995).
9. Okosun, I. S. et al. Hypertension and type 2 diabetes comorbidity in adults in the United States: risk of overall and regional adiposity. Obes. Res. 9, 1-9 (2001).
10. Boland, L. L., Folsom, A. R. & Rosamond, W. D. Hyperinsulinemia, dyslipidemia, and obesity as risk factors for hospitalized gallbladder disease. A prospective study. Ann. Epidemiol. 12, 131-140 (2002).
11. Chen, H. et al. Obesity and the risk of Parkinson's disease. Am. J. Epidemiol. 159, 547-555 (2004).
12. Kalmijn, S. et al. Metabolic cardiovascular syndrome and risk of dementia in Japanese-American elderly men. The Honolulu-Asia aging study. Arterioscler. Thromb. Vasc. Biol. 20, 2255-2560 (2000).
13. Calle, E. E., Rodriguez, C., Walker-Thurmond, K. & Thun, M. J. Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U. S. adults. N. Engl. J. Med. 348, 1625-1638 (2003).
14. St-Onge, M. P., Janssen, I. & Heymsfield, S. B. Metabolic syndrome in normal-weight Americans: new definition of the metabolically obese, normal-weight individual. Diabetes Care 27, 2222-2228 (2004).
15. Freedland, E. S. Role of a critical visceral adipose tissue threshold (CVATT) in metabolic syndrome: implications for controlling dietary carbohydrates: a review. Nutr. Metab. (Lond) 1, 12 (2004).
16. McCay C. M., Crowell, M. F. & Maynard, L. A. The effect of retarded growth upon the length of life and upon the ultimate body size. J. Nutr. 10, 63-79 (1935).
17. Rudzinska, M. A. The influence of amount of food on the reproduction rate and longevity of a sectarian. (Tokophyra infusionum). Science 113, 10-11 (1951).
18. Lin, S. J., Defossez, P. A. & Guarente, L. Requirement of NAD and SIR2 for life-span extension by calorie restriction in Saccharomyces cerevisiae. Science 289, 2126-2128 (2000).
19. Klass, M. R. Aging in the nematode Caenorhabditis elegans: major biological and environmental factors influencing life span. [i Mech. Ageing Dev. 6, 413-429 (1977).
20. Kealy, R. D. et al. Effects of diet restriction on life span and age-related changes in dogs. J. Am. Vet. Med. Assoc. 220, 1315-1320 (2002).
21. Roth, G. S. et al. Aging in rhesus monkeys: relevance to human health interventions. Science 305, 1423-1426 (2004).
22. Heilbronn, L. K. & Ravussin, E. Calorie restriction and aging: review of the literature and implications for studies in humans. Am. J. Clin. Nutr. 78, 361-369 (2003).
23. Bhattacharyya, T. K., Merz, M. & Thomas, J. R. Modulation of cutaneous aging with calorie restriction in Fischer 344 rats: a histological study. Arch. Facial Plast. Surg. 7, 12-16 (2005).
24. Ingram, D. K., Weindruch, R., Spangler, E. L., Freeman, J. R. & Walford, R. L. Dietary restriction benefits learning and motor performance of aged mice. J. Gerontol. 42, 78-81 (1987).
25. Stewart, J., Mitchell, J. & Kalant, N. The effects of life-long food restriction on spatial memory in young and aged Fischer 344 rats measured in the eight-arm radial and the Morris water mazes. Neurobiol. Aging 10, 669-675 (1989).
26. Eckles-Smith, K., Clayton, D., Bickford, P. & Browning, M. D. Caloric restriction prevents age-related deficits in LTP and in NMDA receptor expression. Brain Res. Mol. Brain Res. 78, 154-162 (2000).
27. Mattson, M. P., Duan, W. & Guo, Z. Meal size and frequency affect neuronal plasticity and vulnerability to disease: cellular and molecular mechanisms. J. Neurochem. 84, 417-431 (2003).
28. Saxton, J. A. & Kimball, G. C. Relation to nephrosis and other diseases of albino rat to age and to modifications of diet. Arch. Pathol. 32, 951-965 (1944).
29. Stern, J. S., Gades, M. D., Wheeldon, C. M. & Borchers, A. T. Calorie restriction in obesity: prevention of kidney disease in rodents. J. Nutr. 131, 913S-917S (2001).
30. Gerbase-DeLima, M., Liu, R. K., Cheney, K. E., Mickey, R. & Walford, R. L. Immune function and survival in a long-lived mouse strain subjected to undernutrition. Gerontologia 21, 184-202 (1975).
31. Pahlavani, M. A. Influence of caloric restriction on aging immune system. J. Nutr. Health Aging 8, 38-47 (2004).
32. Guo, Z. et al. Dietary restriction reduces atherosclerosis and oxidative stress in the aorta of apolipoprotein E-deficient mice. Mech. Ageing Dev. 123, 1121-1131 (2002).
33. Rous, F. The influence of diet on transplant and spontaneous tumors. J. Exp. Med. 20, 433-451 (1914).
34. Duan, W. et al. Dietary restriction normalizes glucose metabolism and BDNF levels, slows disease progression, and increases survival in huntingtin mutant mice. Proc. Natl Acad. Sci. USA 100, 2911-2916 (2003).
35. Duan, W. & Mattson, M. P. Dietary restriction and 2-deoxyglucose administration improve behavioral outcome and reduce degeneration of dopaminergic neurons in models of Parkinson's disease. J. Neurosci. Res. 57, 195-206 (1999).
36. Zhu, H., Guo, Q. & Mattson, M. P. Dietary restriction protects hippocampal neurons against the death-promoting action of a presenilin-1 mutation. Brain Res. 842, 224-229 (1999).
37. Friedman, D. B. & Johnson, T. E. A mutation in the age-1 gene in Caenorhabditis elegans lengthens life and reduces hermaphrodite fertility. Genetics 118, 75-86 (1988).
38. Kenyon, C., Chang, J., Gensch, E., Rudner, A. & Tabtiang, R. A C. elegans mutant that lives twice as long as wild type. Nature 366, 461-464 (1993).
39. Kimura, K. D., Tissenbaum, H. A., Liu, Y. & Ruvkun, G. daf-2, an insulin receptor-like gene that regulates longevity and diapause in Caenorhabditis elegans. Science 277, 942-946 (1997).
40. Garigan, D. et al. Genetic analysis of tissue aging in Caenorhabditis elegans: a role for heat-shock factor and bacterial proliferation. Genetics 161, 1101-1112 (2002).
41. Morley, J. F., Brignull, H. R., Weyers, J. J. & Morimoto, R. I. The threshold for polyglutamine-expansion protein aggregation and cellular toxicity is dynamic and influenced by aging in Caenorhabditis elegans. Proc. Natl Acad. Sci. USA 99, 10417-10422 (2002).
42. Huang, C., Xiong, C. & Kornfeld, K. Measurements of age-related changes of physiological processes that predict lifespan of Caenorhabditis elegans. Proc. Natl Acad. Sci. USA 101, 8084-8089 (2004).
43. Lithgow, G. J., White, T. M., Melov, S. & Johnson, T. E. Thermotolerance and extended life-span conferred by single-gene mutations and induced by thermal stress. Proc. Natl Acad. Sci. USA 92, 7540-7504 (1995).
44. Scott, B. A., Avidan, M. S. & Crowder, C. M. Regulation of hypoxic death in C. elegans by the insulin/IGF receptor homolog DAF-2. Science 296, 2388-2391 (2002).
45. Garsin, D. A. et al. Long-lived C. elegans daf-2 mutants are resistant to bacterial pathogens. Science 300, 1921 (2003).
46. Tatar, M. et al. A mutant Drosophila insulin receptor homolog that extends life-span and impairs neuroendocrine function. Science 292, 107-110 (2001).
47. Holzenberger, M. et al. IGF-1 receptor regulates lifespan and resistance to oxidative stress in mice. Nature 421, 182-7 (2003).
48. Bluher, M., Kahn, B. B. & Kahn, C. R. Extended longevity in mice lacking the insulin receptor in adipose tissue. Science 299, 572-574 (2003).
49. Brown-Borg, H. M., Borg, K. E., Meliska, C. J. & Bartke, A. Dwarf mice and the ageing process. Nature 384, 33 (1996).
50. Flurkey, K., Papaconstantinou, J., Miller, R. A. & Harrison, D. E. Lifespan extension and delayed immune and collagen aging in mutant mice with defects in growth hormone production. Proc. Natl Acad. Sci. USA 98, 6736-6741 (2001).
51. Coschigano, K. T., Clemmons, D., Bellush, L. L. & Kopchick, J. J. Assessment of growth parameters and life span of GHR/BP gene-disrupted mice. Endocrinology 141, 2608-2613 (2000).
52. Lin, K., Dorman, J. B., Rodan, A. & Kenyon, C. daf-16: An HNF-3/forkhead family member that can function to double the life-span of Caenorhabditis elegans. Science 278, 1319-1322 (1997).
53. Ogg, S. et al. The Fork head transcription factor DAF-16 transduces insulin-like metabolic and longevity signals in C. elegans. Nature 389, 994-9 (1997).
54. Murphy, C. T. et al. Genes that act downstream of DAF-16 to influence the lifespan of Caenorhabditis elegans. Nature 424, 277-283 (2003).
55. Lee, S. S., Kennedy, S., Tolonen, A. C. & Ruvkun, G. DAF-16 target genes that control C. elegans life-span and metabolism. Science 300, 644-647 (2003).
56. McElwee, J., Bubb, K. & Thomas, J. H. Transcriptional outputs of the Caenorhabditis elegans forkhead protein DAF-16. Aging Cell 2, 111-121 (2003).
57. Hsu, A. L., Murphy, C. T. & Kenyon, C. Regulation of aging and age-related disease by DAF-16 and heat-shock factor. Science 300, 1142-1145 (2003).
58. Morley, J. F. & Morimoto, R. I. Regulation of longevity in Caenorhabditis elegans by heat shock factor and molecular chaperones. Mol. Biol. Cell 15, 657-664 (2004).
59. Hartl, F. U. & Hayer-Hartl, M. Molecular chaperones in the cytosol: from nascent chain to folded protein. Science 295, 1852-1858 (2002).
60. Takayama, S., Reed, J. C. & Homma, S. Heat-shock proteins as regulators of apoptosis. Oncogene 22, 9041-9047 (2003).
61. Apfeld, J., O'Connor, G., McDonagh, T., DiStefano, P. S. & Curtis, R. The AMP-activated protein kinase AAK-2 links energy levels and insulin-like signals to lifespan in C. elegans. Genes Dev. 18, 3004-3009 (2004).
62. Tschape, J. A. et al. The neurodegeneration mutant lochrig interferes with cholesterol homeostasis and Appl processing. EMBO J. 21, 6367-6376 (2002).
63. Harkness, T. A., Shea, K. A., Legrand, C., Brahmania, M. & Davies, G. F. A functional analysis reveals dependence on the anaphase-promoting complex for prolonged life span in yeast. Genetics 168, 759-774 (2004).
64. Hardie, D. G. The AMP-activated protein kinase pathway-new players upstream and downstream. J. Cell Sci. 117, 5479-5487 (2004).
65. Hardie, D. G., Carling, D. & Carlson, M. The AMP-activated/SNF1 protein kinase subfamily: metabolic sensors of the eukaryotic cell? Annu. Rev. Biochem. 67, 821-855 (1998).
66. Owen, M. R., Doran, E. & Halestrap, A. P. Evidence that metformin exerts its anti-diabetic effects through inhibition of complex 1 of the mitochondrial respiratory chain. Biochem. J. 348, 607-614 (2000).
67. Hawley, S. A. et al. Complexes between the LKB1 tumor suppressor, STRADα/β and MO25α/β are upstream kinases in the AMP-activated protein kinase cascade. J. Biol. 2, 28 (2003).
68. Zhou, G. et al. Role of AMP-activated protein kinase in mechanism of metformin action. J. Clin. Invest. 108, 1167-1174 (2001).
69. Fryer, L. G., Parbu-Patel, A. & Carling, D. The Antidiabetic drugs rosiglitazone and metformin stimulate AMP-activated protein kinase through distinct signaling pathways. J. Biol. Chem. 277, 25226-25232 (2002).
70. Dilman, V. M. & Anisimov, V. N. Effect of treatment with phenformin, diphenylhydantoin or L-dopa on life span and tumour incidence in C3H/Sn mice. Gerontology 26, 241-246 (1980).
71. Anisimov, V. N., Semenchenko, A. V. & Yashin, A. I. Insulin and longevity: antidiabetic biguanides as geroprotectors. Biogerontology 4, 297-307 (2003).
72. Yeh, W. C., Cao, Z., Classon, M. & McKnight, S. L. Cascade regulation of terminal adipocyte differentiation by three members of the C/EBP family of leucine zipper proteins. Genes Dev. 9, 168-181 (1995).
73. Chen, S. S., Chen, J. F., Johnson, P. F., Muppala, V. & Lee, Y. H. C/EBPβ, when expressed from the C/EBPα gene locus, can functionally replace C/EBPα in liver but not in adipose tissue. Mol. Cell. Biol. 20, 7292-7299 (2000).
74. Chiu, C. H., Lin, W. D., Huang, S. Y. & Lee, Y. H. Effect of a C/EBP gene replacement on mitochondrial biogenesis in fat cells. Genes Dev. 18, 1970-1975 (2004).
75. Bluher, M. et al. Adipose tissue selective insulin receptor knockout protects against obesity and obesity-related glucose intolerance. Dev. Cell 3, 25-38 (2002).
76. Apfeld, J. & Kenyon, C. Cell nonautonomy of C. elegans daf-2 function in the regulation of diapause and life span. Cell 95, 199-210 (1998).
77. Libina, N., Berman, J. R. & Kenyon, C. Tissue-specific activities of C. elegans DAF-16 in the regulation of lifespan. Cell 115, 489-502 (2003).
78. Giannakou, M. E. et al. Long-lived Drosophila with overexpressed dFOXO in adult fat body. Science 305, 361 (2004).
79. Kershaw, E. E. & Flier, J. S. Adipose tissue as an endocrine organ. J. Clin. Endocrinol. Metab. 89, 2548-2556 (2004).
80. Bluher, M., Patti, M. E., Gesta, S., Kahn, B. B. & Kahn, C. R. Intrinsic heterogeneity in adipose tissue of fat-specific insulin receptor knock-out mice is associated with differences in patterns of gene expression. J. Biol. Chem. 279, 31891-31901 (2004).
81. Nathan, D. M. Long-term complications of diabetes mellitus. N. Engl. J. Med. 328, 1676-1685 (1993).
82. Neel, J. V. Diabetes mellitus: a 'thrifty' genotype rendered detrimental by 'progress'? Am. J. Hum. Genet. 14, 353-362 (1962).
83. Kirkwood, T. L., Kapahi, P. & Shanley, D. P. Evolution, stress, and longevity. J. Anat. 197, 587-90 (2000).
84. Griffin, M. E. et al. Free fatty acid-induced insulin resistance is associated with activation of protein kinase C theta and alterations in the insulin signaling cascade. Diabetes 48, 1270-1274 (1999).
85. Dresner, A. et al. Effects of free fatty acids on glucose transport and IRS-1-associated phosphatidylinositol 3-kinase activity. J. Clin. Invest. 103, 253-259 (1999).
86. Kim, J. K. et al. Tissue-specific overexpression of lipoprotein lipase causes tissue-specific insulin resistance. Proc. Natl Acad. Sci. USA 98, 7522-7527 (2001).
87. Yu, C. et al. Mechanism by which fatty acids inhibit insulin activation of insulin receptor substrate-1 (IRS-1)-associated phosphatidylinositol 3-kinase activity in muscle. J. Biol. Chem. 277, 50230-50236 (2002).
88. Itani, S. I., Ruderman, N. B., Schmieder, F. & Boden, G. Lipid-induced insulin resistance in human muscle is associated with changes in diacylglycerol, protein kinase C, and IκB-α. Diabetes 51, 2005-2011 (2002).
89. Reaven, G. M. Why syndrome X? From Harold Himsworth to the insulin resistance syndrome. Cell Metab. 1, 9-15 (2005).
90. Xu, H. et al. Chronic inflammation in fat plays a crucial role in the development of obesity-related insulin resistance. J. Clin. Invest. 112, 1821-1830 (2003).
91. Weisberg, S. P. et al. Obesity is associated with macrophage accumulation in adipose tissue. J. Clin. Invest. 112, 1796-1808 (2003).
92. Trevisan, M., Liu, J., Bahsas, F. B. & Menotti, A. Syndrome X and mortality: a population-based study. Risk Factor and Life Expectancy Research Group. Am. J. Epidemiol. 148, 958-966 (1998).
93. Rowe, J. W., Minaker, K. L., Pallotta, J. A. & Flier, J. S. Characterization of the insulin resistance of aging. J. Clin. Invest. 71, 1581-1587 (1983).
94. Kohrt, W. M. et al. Insulin resistance in aging is related to abdominal obesity. Diabetes 42, 273-281 (1993).
95. Cefalu, W. T. et al. Contribution of visceral fat mass to the insulin resistance of aging. Metabolism 44, 954-959 (1995).
96. Rocchini, A. P. Obesity hypertension. Am. J. Hypertens. 15, 50S-52S (2002).
97. Cusi, K. et al. Insulin resistance differentially affects the PI 3-kinase- and MAP kinase-mediated signaling in human muscle. J. Clin. Invest. 105, 311-320 (2000).
98. Lawlor, D. A., Smith, G. D. & Ebrahim, S. Hyperinsulinaemia and increased risk of breast cancer: findings from the British Women's Heart and Health Study. Cancer Causes Control 15, 267-275 (2004).
99. Yang, Y. X., Hennessy, S. & Lewis, J. D. Insulin therapy and colorectal cancer risk among type 2 diabetes mellitus patients. Gastroenterology 127, 1044-1050 (2004).
100. Kondo, T. et al. Knockout of insulin and IGF-1 receptors on vascular endothelial cells protects against retinal neovascularization. J. Clin. Invest. 111, 1835-1842 (2003).
101. Facchini, F. S., Hua, N., Abbasi, F. & Reaven, G. M. Insulin resistance as a predictor of age-related diseases. J. Clin. Endocrinol. Metab. 86, 3574-3578 (2001).
102. Barbieri, M., Rizzo, M. R., Manzella, D. & Paolisso, G. Age-related insulin resistance: is it an obligatory finding? The lesson from healthy centenarians. Diabetes Metab Res Rev 17, 19-26 (2001).
103. Kopelman, P. G. The effects of weight loss treatments on upper and lower body fat. Int. J. Obes. Relat. Metab. Disord. 21, 619-625 (1997).
104. Nicklas, B. J. et al. Lifestyle intervention of hypocaloric dieting and walking reduces abdominal obesity and improves coronary heart disease risk factors in obese, postmenopausal, African-American and Caucasian women. J. Gerontol. A Biol. Sci. Med. Sci. 58, 181-189 (2003).
105. Sabir, N., Pakdemirli, E., Sermez, Y., Zencir, M. & Kazil, S. Sonographic assessment of changes in thickness of different abdominal fat layers in response to diet in obese women. J. Clin. Ultrasound 31, 26-30 (2003).
106. Sjostrom, L. et al. Lifestyle, diabetes, and cardiovascular risk factors 10 years after bariatric surgery. N. Engl. J. Med. 351, 2683-2693 (2004).
107. Klein, S. et al. Weight management through lifestyle modification for the prevention and management of type 2 diabetes: rationale and strategies: a statement of the American Diabetes Association, the North American Association for the Study of Obesity, and the American Society for Clinical Nutrition. Diabetes Care 27, 2067-2073 (2004).
108. Williamson, D. F., Vinicor, F. & Bowman, B. A. Primary prevention of type 2 diabetes mellitus by lifestyle intervention: implications for health policy. Ann. Intern. Med. 140, 951-957 (2004).
109. Dixon, J. B., Anderson, M., Cameron-Smith, D. & O'Brien, P. E. Sustained weight loss in obese subjects has benefits that are independent of attained weight. Obes. Res. 12, 1895-902 (2004).
110. Kelley, D. E. et al. Relative effects of calorie restriction and weight loss in noninsulin-dependent diabetes mellitus. J. Clin. Endocrinol. Metab. 77, 1287-93 (1993).
111. Wadden, T. A. & Foster, G. D. Behavioral treatment of obesity. Med. Clin. North Am. 84, 441-461 (2000).
112. Scheen, A. J. Is there a role for α-glucosidase inhibitors in the prevention of type 2 diabetes mellitus? Drugs 63, 933-951 (2003).
113. Chiasson, J. L. et al. Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance: the STOP-NIDDM trial. JAMA 290, 486-494 (2003).
114. Chiasson, J. L. et al. Acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomised trial. Lancet 359, 2072-2077 (2002).
115. Heck, A. M., Yanovski, J. A. & Calis, K. A. Orlistat, a new lipase inhibitor for the management of obesity. Pharmacotherapy 20, 270-279 (2000).
116. Yanovski, S. Z. & Yanovski, J. A. Obesity. N. Engl. J. Med. 346, 591-602 (2002).
117. McMahon, F. G. et al. Efficacy and safety of sibutramine in obese white and African American patients with hypertension: a 1-year, double-blind, placebo-controlled, multicenter trial. Arch. Intern. Med. 160, 2185-2191 (2000).
118. Flier, J. S. Obesity wars: molecular progress confronts an expanding epidemic. Cell 116, 337-350 (2004).
119. Holst, B., Cygankiewicz, A., Jensen, T. H., Ankersen, M. & Schwartz, T. W. High constitutive signaling of the ghrelin receptor - identification of a potent inverse agonist. Mol. Endocrinol. 17, 2201-2210 (2003).
120. Borowsky, B. et al. Antidepressant, anxiolytic and anorectic effects of a melanin-concentrating hormone-1 receptor antagonist. Nature Med. 8, 825-830 (2002).
121. Boyce, R. S. & Duhl, D. M. Melanocortin-4 receptor agonists for the treatment of obesity. Curr. Opin. Investig. Drugs 5, 1063-1071 (2004).
122. Black, S. C. Cannabinoid receptor antagonists and obesity. Curr. Opin. Investig. Drugs 5, 389-394 (2004).
123. Gabriely, I. et al. Removal of visceral fat prevents insulin resistance and glucose intolerance of aging: an adipokine-mediated process? Diabetes 51, 2951-2958 (2002).
124. Thorne, A., Lonnqvist, F., Apelman, J., Hellers, G. & Arner, P. A pilot study of long-term effects of a novel obesity treatment: omentectomy in connection with adjustable gastric banding. Int. J. Obes. Relat. Metab. Disord. 26, 193-199 (2002).
125. Klein, S. et al. Absence of an effect of liposuction on insulin action and risk factors for coronary heart disease. N. Engl. J. Med. 350, 2549-2557 (2004).
126. Toriyama, K. et al. Endogenous adipocyte precursor cells for regenerative soft-tissue engineering. Tissue Eng. 8, 157-165 (2002).
127. Wang, Y. X. et al. Peroxisome-proliferator-activated receptor δ activates fat metabolism to prevent obesity. Cell 113, 159-170 (2003).
128. Festa, A. et al. Chronic subclinical inflammation as part of the insulin resistance syndrome: the Insulin Resistance Atherosclerosis Study (IRAS). Circulation 102, 42-47 (2000).
129. Krabbe, K. S., Pedersen, M. & Bruunsgaard, H. Inflammatory mediators in the elderly. Exp. Gerontol. 39, 687-699 (2004).
130. Duncan, B. B. et al. Low-grade systemic inflammation and the development of type 2 diabetes: the atherosclerosis risk in communities study. Diabetes 52, 1799-1805 (2003).
131. Pradhan, A. D., Manson, J. E., Rifai, N., Buring, J. E. & Ridker, P. M. C-reactive protein, interleukin 6, and risk of developing type 2 diabetes mellitus. JAMA 286, 327-334 (2001).
132. Glass, C. K. & Witztum, J. L. Atherosclerosis. the road ahead. Cell 104, 503-516 (2001).
133. Schmidt, R. et al. Early inflammation and dementia: a 25-year follow-up of the Honolulu-Asia Aging Study. Ann. Neurol. 52, 168-174 (2002).
134. Yuan, M. et al. Reversal of obesity- and diet-induced insulin resistance with salicylates or targeted disruption of Ikkβ. Science 293, 1673-1677 (2001).
135. Hundal, R. S. et al. Mechanism by which high-dose aspirin improves glucose metabolism in type 2 diabetes. J. Clin. Invest. 109, 1321-1326 (2002).
136. Palladino, M. A., Bahjat, F. R., Theodorakis, E. A. & Moldawer, L. L. Anti-TNF-α therapies: the next generation. Nature Rev. Drug Discov. 2, 736-746 (2003).
137. Satapathy S. K. et al. Beneficial effects of tumor necrosis factor-α inhibition by pentoxifylline on clinical, biochemical, and metabolic parameters of patients with nonalcoholic steatohepatitis. Am. J. Gastroenterol. 99, 1946-1952 (2004).
138. Park, H. et al. Coordinate regulation of malonyl-CoA decarboxylase, sn-glycerol-3-phosphate acyltransferase, and acetyl-CoA carboxylase by AMP-activated protein kinase in rat tissues in response to exercise. J. Biol. Chem. 277, 32571-32577 (2002).
139. Mu, J., Brozinick, J. T., Jr., Valladares, O., Bucan, M. & Birnbaum, M. J. A role for AMP-activated protein kinase in contraction- and hypoxia-regulated glucose transport in skeletal muscle. Mol. Cell 7, 1085-1094 (2001).
140. Bergeron, R. et al. Chronic activation of AMP kinase results in NRF-1 activation and mitochondrial biogenesis. Am. J. Physiol. Endocrinol. Metab. 281, E1340-E1346 (2001).
141. Zong, H. et al. AMP kinase is required for mitochondrial biogenesis in skeletal muscle in response to chronic energy deprivation. Proc. Natl Acad. Sci. USA 99, 15983-15987 (2002).
142. Aschenbach, W. G., Sakamoto, K. & Goodyear, L. J. 5′ adenosine monophosphate-activated protein kinase, metabolism and exercise. Sports Med. 34, 91-103 (2004).
143. Hu, F. B. et al. Adiposity as compared with physical activity in predicting mortality among women. N. Engl. J. Med. 351, 2694-2703 (2004).
144. Ruderman, N. & Prentki, M. AMP kinase and malonyl-CoA: targets for therapy of the metabolic syndrome. Nature Rev. Drug Discov. 3, 340-351 (2004).
145. Pasquali, R. et al. Effect of long-term treatment with metformin added to hypocaloric diet on body composition, fat distribution, and androgen and insulin levels in abdominally obese women with and without the polycystic ovary syndrome. J. Clin. Endocrinol. Metab. 85, 2767-2774 (2000).
146. Hundal, R. S. & Inzucchi, S. E. Metformin: new understandings, new uses. Drugs 63, 1879-1894 (2003).
147. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group. Lancet 352, 854-865 (1998).
148. Inoki, K., Zhu, T. & Guan, K. L. TSC2 mediates cellular energy response to control cell growth and survival. Cell 115, 577-590 (2003).
149. Vellai, T. et al. Genetics: influence of TOR kinase on lifespan in C. elegans. Nature 426, 620 (2003).
150. Kapahi, P. et al. Regulation of lifespan in Drosophila by modulation of genes in the TOR signaling pathway. Curr. Biol. 14, 885-890 (2004).
151. Bjornsti, M. A. & Houghton, P. J. The TOR pathway: a target for cancer therapy. Nat Rev Cancer 4, 335-348 (2004).
152. Um, S. H. et al. Absence of S6K1 protects against age- and diet-induced obesity while enhancing insulin sensitivity. Nature 431, 200-205 (2004).
153. Abu-Elheiga, L., Matzuk, M. M., Abo-Hashema, K. A. & Wakil, S. J. Continuous fatty acid oxidation and reduced fat storage in mice lacking acetyl-CoA carboxylase 2. Science 291, 2613-2616 (2001).
154. Abu-Elheiga, L., Oh, W., Kordari, P. & Wakil, S. J. Acetyl-CoA carboxylase 2 mutant mice are protected against obesity and diabetes induced by high-fat/high-carbohydrate diets. Proc. Natl Acad. Sci. USA 100, 10207-10212 (2003).
155. Tobert, J. A. Lovastatin and beyond: the history of the HMG-CoA reductase inhibitors. Nature Rev. Drug Discov. 2, 517-526 (2003).
156. Longo, V. D. & Finch, C. E. Evolutionary medicine: from dwarf model systems to healthy centenarians? Science 299, 1342-1346 (2003).
157. Hauck, S. J., Hunter, W. S., Danilovich, N., Kopchick, J. J. & Bartke, A. Reduced levels of thyroid hormones, insulin, and glucose, and lower body core temperature in the growth hormone receptor /binding protein knockout mouse. Exp. Biol. Med. (Maywood) 226, 552-558 (2001).
158. Bartke, A. Growth hormone and aging. Endocrine 8, 103-8 (1998).
159. Bartke, A. Can growth hormone (GH) accelerate aging? Evidence from GH-transgenic mice. Neuroendocrinology 78, 210-216 (2003).
160. Laron, Z. Do deficiencies in growth hormone and insulin-like growth factor-1 (IGF-1) shorten or prolong longevity? Mech. Ageing Dev. 126, 305-307 (2005).
161. Berryman, D. E. et al. Comparing adiposity profiles in three mouse models with altered GH signaling. Growth Horm. IGF Res. 14, 309-318 (2004).
162. Boehm, B. O. & Lustig, R. H. Use of somatostatin receptor ligands in obesity and diabetic complications. Best Pract. Res. Clin. Gastroenterol. 16, 493-509 (2002).
163. Lustig, R. H. et al. Hypothalamic obesity caused by cranial insult in children: altered glucose and insulin dynamics and reversal by a somatostatin agonist. J. Pediatr. 135, 162-168 (1999).
164. Lamberts, S. W., de Herder, W. W. & Holland, L. J. Somatostatin analogs in the diagnosis and treatment of cancer. Trends Endocrinol. Metab. 13, 451-457 (2002).
165. Grant, M. B. & Caballero, S. Somatostatin analogues as drug therapies for retinopathies. Drugs Today (Barc) 38, 783-791 (2002).
166. Drake, W. M., Parkinson, C., Besser, G. M. & Trainer, P. J. Clinical use of a growth hormone receptor antagonist in the treatment of acromegaly. Trends Endocrinol. Metab. 12, 408-413 (2001).
167. Dagnaes-Hansen, F., Duan, H., Rasmussen, L. M., Friend, K. E. & Flyvbjerg, A. Growth hormone receptor antagonist administration inhibits growth of human colorectal carcinoma in nude mice. Anticancer Res. 24, 3735-3742 (2004).
168. Vance, M. L. Can growth hormone prevent aging? N. Engl. J. Med. 348, 779-780 (2003).
169. Blackman, M. R. et al. Growth hormone and sex steroid administration in healthy aged women and men: a randomized controlled trial. JAMA 288, 2282-2292 (2002).
170. Imai, S., Armstrong, C. M., Kaeberlein, M. & Guarente, L. Transcriptional silencing and longevity protein Sir2 is an NAD-dependent histone deacetylase. Nature 403, 795-800 (2000).
171. Kaeberlein, M., McVey, M. & Guarente, L. The SIR2/3/4 complex and SIR2 alone promote longevity in Saccharomyces cerevisiae by two different mechanisms. Genes Dev. 13, 2570-2580 (1999).
172. Tissenbaum, H. A. & Guarente, L. Increased dosage of a sir-2 gene extends lifespan in Caenorhabditis elegans. Nature 410, 227-230 (2001).
173. Rogina, B. & Helfand, S. L. Sir2 mediates longevity in the fly through a pathway related to calorie restriction. Proc. Natl Acad. Sci. USA 101, 15998-16003 (2004).
174. Tanner, K. G., Landry, J., Sternglanz, R. & Denu, J. M. Silent information regulator 2 family of NAD- dependent histone/protein deacetylases generates a unique product, 1-O-acetyl-ADP-ribose. Proc. Natl Acad. Sci. USA 97, 14178-14182 (2000).
175. Berger, F., Ramirez-Hernandez, M. H. & Ziegler, M. The new life of a centenarian: signalling functions of NAD(P). Trends Biochem. Sci. 29, 111-118 (2004).
176. Sauve, A. A., Moir, R. D., Schramm, V. L. & Willis, I. M. Chemical Activation of Sir2- Dependent Silencing by Relief of Nicotinamide Inhibition. Mol. Cell 17, 595-601 (2005).
177. Motta, M. C. et al. Mammalian SIRT1 represses forkhead transcription factors. Cell 116, 551-563 (2004).
178. van der Horst, A. et al. FOXO4 is acetylated upon peroxide stress and deacetylated by the longevity protein hSir2(SIRT1). J. Biol. Chem. 279, 28873-28879 (2004).
179. Brunet, A. et al. Stress-dependent regulation of FOXO transcription factors by the SIRT1 deacetylase. Science 303, 2011-2015 (2004).
180. Daitoku, H. et al. Silent information regulator 2 potentiates Foxo1-mediated transcription through its deacetylase activity. Proc. Natl Acad. Sci. USA 101, 10042-10047 (2004).
181. Shi, T., Wang, F., Stieren, E. & Tong, Q. SIRT3, a mitochondrial Sirtuin deacetylase, regulates mitochondrial function and thermogenesis in Brown adipocytes. J. Biol. Chem. 280, 13560-13567 (2005).
182. Cohen, H. Y. et al. Calorie restriction promotes mammalian cell survival by inducing the SIRT1 deacetylase. Science 305, 390-392 (2004).
183. Picard, F. et al. Sirt1 promotes fat mobilization in white adipocytes by repressing PPAR-γ. Nature 429, 771-776 (2004).
184. Rodgers, J. T. et al. Nutrient control of glucose homeostasis through a complex pf PGC-1α and SIRT1. Nature 3354 (2005).
185. Rogina, B., Reenan, R. A., Nilsen, S. P. & Helfand, S. L. Extended life-span conferred by cotransporter gene mutations in Drosophila. Science 290, 2137-2140 (2000).
186. Fei, Y. J. et al. Relevance of NAC-2, an Na+-coupled citrate transporter, to life span, body size and fat content in Caenorhabditis elegans. Biochem. J. 379, 191-198 (2004).
187. Knauf, F., Rogina, B., Jiang, Z., Aronson, P. S. & Helfand, S. L. Functional characterization and immunolocalization of the transporter encoded by the life-extending gene Indy. Proc. Natl Acad. Sci. USA 99, 14315-14319 (2002).
188. Inoue, K. et al. Functional identity of Drosophila melanogaster Indy as a cation-independent, electroneutral transporter for tricarboxylic acid-cycle intermediates. Biochem. J. 367, 313-319 (2002).
189. Inoue, K., Zhuang, L. & Ganapathy, V. Human Na+-coupled citrate transporter: primary structure, genomic organization, and transport function. Biochem. Biophys. Res. Commun. 299, 465-471 (2002).
190. Inoue, K., Zhuang, L., Maddox, D. M., Smith, S. B. & Ganapathy, V. Human sodium-coupled citrate transporter, the orthologue of Drosophila Indy, as a novel target for lithium action. Biochem. J. 374, 21-26 (2003).
191. Chen, Y. & Silverstone, T. Lithium and weight gain. Int. Clin. Psychopharmacol. 5, 217-225 (1990).
192. DePinho, R. A. The age of cancer. Nature 408, 248-254 (2000).
193. Malone, E. A., Inoue, T. & Thomas, J. H. Genetic analysis of the roles of daf-28 and age-1 in regulating Caenorhabditis elegans dauer formation. Genetics 143, 1193-1205 (1996).
194. Kawano, T. et al. Molecular cloning and characterization of a new insulin/IGF-like peptide of the nematode Caenorhabditis elegans. Biochem. Biophys. Res. Commun. 273, 431-436 (2000).
195. Li, W., Kennedy, S. G. & Ruvkun, G. daf-28 encodes a C. elegans insulin superfamily member that is regulated by environmental cues and acts in the DAF-2 signaling pathway. Genes Dev. 17, 844-858 (2003).
196. Pierce, S. B. et al. Regulation of DAF-2 receptor signaling by human insulin and ins-1, a member of the unusually large and diverse C. elegans insulin gene family. Genes Dev. 15, 672-686 (2001).
197. Clancy, D. J. et al. Extension of life-span by loss of CHICO, a Drosophila insulin receptor substrate protein. Science 292, 104-106 (2001).
198. Wolkow, C. A., Munoz, M. J., Riddle, D. L. & Ruvkun, G.
199. Morris, J. Z., Tissenbaum, H. A. & Ruvkun, G. A phosphatidylinositol-3-OH kinase family member regulating longevity and diapause in Caenorhabditis elegans. Nature 382, 536-539 (1996).
200. Dorman, J. B., Albinder, B., Shroyer, T. & Kenyon, C. The age-1 and daf-2 genes function in a common pathway to control the lifespan of Caenorhabditis elegans. Genetics 141, 1399-1406 (1995).
201. Larsen, P. L., Albert, P. S. & Riddle, D. L. Genes that regulate both development and longevity in Caenorhabditis elegans. Genetics 139, 1567-1583 (1995).
202. Ogg, S. & Ruvkun, G. The C. elegans PTEN homolog, DAF-18, acts in the insulin receptor-like metabolic signaling pathway. Mol. Cell 2, 887-893 (1998).
203. Gil, E. B., Malone Link, E., Liu, L. X., Johnson, C. D. & Lees, J. A. Regulation of the insulin-like developmental pathway of Caenorhabditis elegans by a homolog of the PTEN tumor suppressor gene. Proc. Natl Acad. Sci. USA 96, 2925-2930 (1999).
204. Mihaylova, V. T., Borland, C. Z., Manjarrez, L., Stern, M. J. & Sun, H. The PTEN tumor suppressor homolog in Caenorhabditis elegans regulates longevity and dauer formation in an insulin receptor-like signaling pathway. Proc. Natl Acad. Sci. USA 96, 7427-7432 (1999).
205. Rouault, J. P. et al. Regulation of dauer larva development in Caenorhabditis elegans by daf-18, a homologue of the tumour suppressor PTEN. Curr. Biol. 9, 329-332 (1999).
206. Paradis, S., Ailion, M., Toker, A., Thomas, J. H. & Ruvkun, G. A PDK1 homolog is necessary and sufficient to transduce AGE-1 PI3 kinase signals that regulate diapause in Caenorhabditis elegans. Genes Dev. 13, 1438-1452 (1999).
207. Paradis, S. & Ruvkun, G. Caenorhabditis elegans Akt/PKB transduces insulin receptor-like signals from AGE-1 PI3 kinase to the DAF-16 transcription factor. Genes Dev. 12, 2488-2498 (1998).
208. Hertweck, M., Gobel, C. & Baumeister, R. C. elegans SGK-1 is the critical component in the Akt/PKB kinase complex to control stress response and life span. Dev. Cell 6, 577-588 (2004).
209. Fabrizio, P., Pozza, F., Pletcher, S. D., Gendron, C. M. & Longo, V. D. Regulation of longevity and stress resistance by Sch9 in yeast. Science 292, 288-290 (2001).
210. Hwangbo, D. S., Gersham, B., Tu, M. P., Palmer, M. & Tatar, M. Drosophila dFOXO controls lifespan and regulates insulin signalling in brain and fat body. Nature 429, 562-566 (2004).
211. Yokoyama, K. et al. Extended longevity of Caenorhabditis elegans by knocking in extra copies of hsp70F, a homolog of mot-2 (mortalin)/mthsp70/Grp75. FEBS Lett. 516, 53-57 (2002).
212. Tatar, M., Khazaeli, A. A. & Curtsinger, J. W. Chaperoning extended life. Nature 390, 30 (1997).
213. Wang, M. C., Bohmann, D. & Jasper, H. JNK signaling confers tolerance to oxidative stress and extends lifespan in Drosophila. Dev. Cell 5, 811-816 (2003).
214. Walker, G. A. & Lithgow, G. J. Lifespan extension in C. elegans by a molecular chaperone dependent upon insulin-like signals. Aging Cell 2, 131-139 (2003).
215. Morrow, G., Samson, M., Michaud, S. & Tanguay, R. M. Overexpression of the small mitochondrial Hsp22 extends Drosophila life span and increases resistance to oxidative stress. FASEB J. 18, 598-599 (2004).
216. Migliaccio, E. et al. The p66shc adaptor protein controls oxidative stress response and life span in mammals. Nature 402, 309-313 (1999).
217. Perls, T., Kunkel, L. & Puca, A. The genetics of aging. Curr. Opin. Genet. Dev. 12, 362-369 (2002).
218. Puca, A. A. et al. A genome-wide scan for linkage to human exceptional longevity identifies a locus on chromosome 4. Proc. Natl Acad. Sci. USA 98, 10505-10508 (2001).
219. Geesaman, B. J. et al. Haplotype-based identification of a microsomal transfer protein marker associated with the human lifespan. Proc. Natl Acad. Sci. USA 100, 14115-20 (2003).
220. Barzilai, N. et al. Unique lipoprotein phenotype and genotype associated with exceptional longevity. JAMA 290, 2030-2040 (2003).
221. Atzmon, G., Rincon, M., Rabizadeh, P. & Barzilai, N. Biological evidence for inheritance of exceptional longevity. Mech. Ageing Dev. 126, 341-345 (2005).
222. Schachter, F. et al. Genetic associations with human longevity at the APOE and ACE loci. Nature Genet. 6, 29-32 (1994).
223. Harwood, H. J., Jr. et al. Isozyme-nonselective N-substituted bipiperidylcarboxamide acetyl-CoA carboxylase inhibitors reduce tissue malonyl-CoA concentrations, inhibit fatty acid synthesis, and increase fatty acid oxidation in cultured cells and in experimental animals. J. Biol. Chem. 278, 37099-37111 (2003).
224. McCune, S. A. & Harris, R. A. Mechanism responsible for 5-(tetradecyloxy)-2-furoic acid inhibition of hepatic lipogenesis. J. Biol. Chem. 254, 10095-10101 (1979).
225. Kohn, D. T. & Kopchick, J. J. Growth hormone receptor antagonists. Minerva Endocrinol. 27, 287-298 (2002).